Intravenous Fish Oil in Critically Ill Cardiac Patients

• Status: Completed
• Trial end date: 2011-04-01
• Target enrollment: 0
• Participant gender: All

Summary

A large body of evidence has accumulated showing that n-3 PUFAs exert extensive cardiac effects. The development of commercial solutions of FO opens perspectives for therapeutic applications in patients with acute cardiac conditions.the 3 following hypotheses will be addressed in patients requiring cardiac surgery under cardiopulmonary bypass or after myocardial infarction:perioperative /post-PTCA intravenous fish oil modifies the composition of membrane phospholipids in platelets and cardiac cells, blunts the physiological response to cardiac surgery/myocardial infarction, and reduces the incidence of arrhythmias, and reduces the occurrence of systolic dysfunction.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Centre Hospitalier Universitaire Vaudois

Criteria

Inclusion Criteria:

• Coronary artery disease requiring elective surgical repair under cardiopulmonary bypass

• Acute myocardial infarction requiring ICU management

Exclusion Criteria:

• Absence of consent

• Ventricular ejection fraction < 35%

• Beating heart surgery or emergency surgery

• Hypercholesterolemia > 5 mmol/l

• Thrombolysis

• Chronic steroid therapy

• Acute or chronic renal failure prior to surgery (plasma creatinine > 150 umol/l)

• Chronic coagulation disorder

• Premenopausal female

• Consumption of more than 3 times fish per week